ALEX WEISS, M.D.; WILLIAM J. SCIALES, M.D.
The suspicion that a new therapeutic agent may have ulcerogenic potentialities is a matter of great practical concern to the physician. The belief that compounds like the salicylates, steroids, ACTH, and phenylbutazone may induce peptic ulceration by stimulating acid secretion or by diminishing gastroduodenal tissue resistance in susceptible individuals has facilitated the institution of preventive measures, when use of the drug is unavoidable and when the expected benefit warrants the risk involved (1-3).
Up to the present, little has been written in this regard concerning the oral antidiabetic agent, tolbutamide, a sulfonylurea compound with hypoglycemic effects (4-6). In general, few
WEISS A, SCIALES WJ. The Effect of Tolbutamide on Human Basal Gastric Secretion. Ann Intern Med. ;55:406–415. doi: 10.7326/0003-4819-55-3-406
Download citation file:
Published: Ann Intern Med. 1961;55(3):406-415.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use